Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

CJC-1131. ConjuChem.

Nick Giannoukakis¹

¹University of Pittsburgh School of Medicine, Diabetes Institute, 3460 Fifth Avenue, Pittsburgh, PA 15213, USA. ngiann1@pitt.edu

Current Opinion in Investigational Drugs (London, England : 2000)

|December 3, 2003

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Longitudinal proteomics of leptin treatment in humans with acute and chronic energy deficiency-induced hypoleptinemia reveal novel, mainly immune-related, pleiotropic effects.

Metabolism: clinical and experimental·2024

Same author

Editorial: Diabetes and non-alcoholic fatty liver disease: points of physiological and mechanistic intersection and current co-therapeutic approaches.

Frontiers in endocrinology·2023

Same author

Uncoupling hepatic insulin resistance - hepatic inflammation to improve insulin sensitivity and to prevent impaired metabolism-associated fatty liver disease in type 2 diabetes.

Frontiers in endocrinology·2023

Same author

Tolerogenic dendritic cells in type 1 diabetes: no longer a concept.

Frontiers in immunology·2023

Same author

Response to Comment on Pietropaolo et al. Incidence of an Insulin-Requiring Hyperglycemic Syndrome in SARS-CoV-2- Infected Young Individuals: Is It Type 1 Diabetes? Diabetes 2022;71:2656-2663.

Diabetes·2022

Same author

Hydrogel Dressings for Chronic Wound Healing in Diabetes: Beyond Hydration.

Journal of pharmaceutics & drug delivery research·2022

Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011

Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010

See all related articles

ConjuChem is developing CJC-1131, a novel drug conjugate targeting type 2 diabetes. This glucagon-like peptide 1-based therapy completed a phase I/II trial, with phase II trials anticipated.

Area of Science:

Pharmacology
Endocrinology
Drug Development

Background:

Type 2 diabetes is a growing global health concern.
Existing treatments for type 2 diabetes have limitations.
Novel therapeutic approaches are needed to improve glycemic control.

Purpose of the Study:

To evaluate the safety and efficacy of CJC-1131, a drug affinity complex conjugate.
To assess the potential of CJC-1131 as a treatment for type 2 diabetes.

Main Methods:

Completion of a phase I/II clinical trial for CJC-1131.
Preparation for a subsequent phase II clinical trial.

Main Results:

The phase I/II trial of CJC-1131 was successfully completed in August 2003.

Related Experiment Videos

Data from the completed trial informed the progression to further clinical development.

Conclusions:

CJC-1131 shows promise as a potential new therapy for type 2 diabetes.
Further clinical investigation in phase II trials is warranted.